Skip to main content
PULM
NASDAQ Life Sciences

Pulmatrix Q3: Cash Down to $1.4M, Going Concern, Merger Closing by Year-End

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.45
Mkt Cap
$4.858M
52W Low
$1.06
52W High
$4.98
52W Position info
37% above low
Off High info
71% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PULM sits 37% above its 52-week low of $1.06.

Summary

Pulmatrix reported Q3 2026 results with cash down to $1.4 million, a going-concern assumption, and a merger with Eos SENOLYTIX now expected to close by year-end pending Nasdaq listing approval and the approved reverse split.


Key Events · Earnings and Guidance · PULM

  • Q3 Cash Falls to $1.4 Million

    Cash and cash equivalents were $1.4 million at September 30, 2026, down from $4.1 million at December 31, 2025, with another $0.7 million in restricted cash that becomes unrestricted only on or around the merger closing.

  • Going-Concern Assumption Disclosed

    The unaudited financial statements were prepared assuming the Company continues as a going concern, and management says current cash funds operations only through the anticipated close of the Eos SENOLYTIX merger.

  • Q3 Loss $1.2 Million

    Net loss was $1.2 million ($0.34 per share) for the quarter and $3.4 million ($0.95 per share) for the nine months; G&A rose about $0.4 million to $1.2 million on merger-related legal and professional costs while R&D was under $0.1 million.

  • Merger Guided to Close by Year-End

    The Eos SENOLYTIX merger is now expected to close in November 2026 or by year-end, subject to Nasdaq approval of the listing of merger shares, completion of the reverse stock split approved October 26, 2026, and customary closing conditions.


Analysis · PULM · Life Sciences

Pulmatrix ended September 30 with $1.4 million in cash plus $0.7 million of restricted cash that frees up only on or around the merger closing, against $4.1 million at the start of the year. The company states its unaudited financials were prepared assuming it continues as a going concern, and that current cash funds operations only through the anticipated close of the Eos SENOLYTIX merger. That makes the deal the whole thesis: management now guides the close to November 2026 / by year-end, contingent on Nasdaq listing approval and the reverse stock split stockholders already approved on October 26. If either slips, there is no disclosed funding backstop beyond the $1.0 million Series B private placement struck back in March.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PULM was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.06 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PULM - Latest Insights

PULM
Nov 17, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.40 info
Change: Low Volume info
Market Cap: $4.858M info
PULM
Oct 27, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.40 info
Change: Low Volume info
Market Cap: $4.858M info
PULM
Sep 25, 2026, 4:42 PM EDT
Filing Type: DEFM14A
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $1.40 info
Change: Low Volume info
Market Cap: $4.858M info
PULM
Sep 17, 2026, 4:37 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $1.43
Real-time Price: $1.40 info
Change: Low Volume info
Market Cap: $4.858M info
PULM
Sep 04, 2026, 5:29 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $1.40 info
Change: Low Volume info
Market Cap: $4.858M info